Hemogenyx Pharmaceuticals (LON:HEMO) Trading Up 4.9% – Still a Buy?

Hemogenyx Pharmaceuticals Plc (LON:HEMO) shares were up 4.9% during trading on Monday . The company traded as high as GBX 998 and last traded at GBX 976. Approximately 13,050 shares traded hands during trading, a decline of 58% from the average daily volume of 30,921 shares. The stock had previously closed at GBX 930.15.

Hemogenyx Pharmaceuticals Stock Down 3.0%

The company has a quick ratio of 6.72, a current ratio of 0.43 and a debt-to-equity ratio of -440.54. The company has a market capitalization of £53.92 million, a PE ratio of -3.63 and a beta of 1.56. The stock has a 50-day moving average of GBX 1,003.23 and a 200 day moving average of GBX 860.19.

About Hemogenyx Pharmaceuticals

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.